Filing Flows › Sanara MedTech (SMTI) › Q1 2025
Sanara MedTech (SMTI) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 14, 2025
Sanara MedTech (SMTI) reported revenue of $23.4M for the first quarter 2025 (Q1 2025), +26% from a year earlier and -11% from the quarter before. Operating margin was -8.9%, net loss $3.5M (15.1% of revenue).
Sanara MedTech, Q1 2025: revenue $23.4M (+26% year over year), operating margin -8.9%, net loss $3.5M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $23.4M | -11% | +26% |
| Operating profit | −$2.1M | — | — |
| Net earnings | −$3.5M | — | — |
| Operating cash flow | −$2.0M | -314% | — |
What changed
Revenue was $23.4M in Q1 2025, up 26% year over year and down 11% from the previous quarter. Soft Tissue Repair Products was the largest line at 88% of revenue. Soft Tissue Repair Products added $4.5M year over year (up 28%), 91% of the total change.
Gross margin was 92.2%, up 2.4 points from a year earlier. Operating costs exceeded revenue by $2.1M, an operating margin of -8.9%. Operating expenses grew 30% against revenue growth of 26%. The fastest-growing cost line was SG&A (+32%). The quarter ended with a net loss of $3.5M, wider than the previous quarter's $1.7M loss.
Operating cash flow was −$2.0M. Non-cash charges added back $1.1M of depreciation and amortization and $1.3M of share-based compensation. Working capital and other items used $901K. Capital expenditures of $1.7M exceeded it, leaving free cash flow of −$3.7M.
Questions
What was Sanara MedTech's revenue in the first quarter 2025?
Sanara MedTech (SMTI) reported revenue of $23.4M for the first quarter 2025 (Q1 2025), +26% from a year earlier and -11% from the quarter before.
Was Sanara MedTech profitable in the first quarter 2025?
Operating loss was $2.1M (-8.9% of revenue) and net loss $3.5M.
Source: Sanara MedTech 10-Q on SEC EDGAR.